Phragma Therapeutics Inc. and its Greek Subsidiary Thera Phragma IKE is a biotechnology company specializing in the research and development of innovative therapies to address diseases related to the function of biological protective barriers of vital organs, such as the brain, the eye, and the intestine. The company's leading program aims to restore the pathological function of the Blood-Brain Barrier (BBB) to treat Central Nervous System (CNS) conditions of high unmet medical need.The company is also developing a proprietary platform technology to enhance the permeability of therapeutic agents (such as gene, cell, and RNA therapies, as well as other macromolecules) into the CNS, improving their efficacy and targeted action in patients with brain disorders.

Lipocine is a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders. Lipocine's technology aims at improving compliance, absorption, and more using proprietary drug delivery technologies.

Encephalos is a life sciences consulting firm passionate for data-driven discovery, development and commercialization of transformational treatments using digital innovation, artificial intelligence, cutting-edge science coupled with operational excellence, deep understanding of the regulatory environment and patient empathy.

@VigilNeuroscience is the world’s first microglia-focused therapeutics company. Our purpose is clear: to treat rare and common neurodegenerative diseases by restoring the vigilance of #microglia, the sentinel cells of the brain’s immune system. We are utilizing the tools of modern #neuroscience drug development across multiple therapeutic modalities to rapidly deliver precision-based therapies to improve the lives of #patients and their families.

Provides Residents/Fellows training and fosters academic research collaborations in the field of Movement Disorders.

Adamas is a fully integrated pharmaceutical company experienced in drug discovery, development, and delivery of treatments for neurological diseases.We are driven by a deep sense of purpose – to make everyday life significantly better for people affected by neurological disorders.

OccamzRazor is a machine learning (ML) powered biotech company with a unique discoveryplatform to tackle brain- aging and brain-aging related disorders starting with Parkinson’s.

Maintains active cross-functional academic research collaborations in the field of Movement Disorders

Head of the Clinical Development Function, Advisor to Acadia's President and CEO and Member of the Executive Leadership Team

Development and validation of technology/digital health solutions impacting patient care, treatment and clinical research

Developing leading-edge gene therapies to deliver dramatic clinical efficacy for the treatment of neurological diseases.

Leads Cavion's R&D Organization (www.cavionpharma.com) with a mission to "Restore the Brain's Natural Rhythms" by modulating overactive T-type calcium channels for a range of neurological and rare genetic diseases.

Therapeutic Area Head responsible for clinical development strategy and execution for Neurodegeneration and Movement Disorders globally.

Global Clinical Lead responsible for development and execution of clinical translation and development strategies in Neurosciences. Responsible for a portfolio of 6 programs across Neurology, Psychiatry and Rare Diseases and a team of Director-level reports.

Served as Medical Affairs Lead responsible for peri/post-approval & life cycle activities in Neurology/Neurosciences (movement disorders/orphan indications, spasticity, headache, pain) for multiple products (including BOTOX). Key contributor to successful NDA fillings, label expansions and product/new indication launches. Managed Medical Affairs Neuroscience budget and mainained a team of several direct reports.

Served as the Medical Director for Biogen Idec’s neurodegenerative disease R&D portfolio (Parkinson’s disease and Alzheimer’s disease). Participated in multiple sclerosis clinical research projects

Directed Clinical and Translational research in the Division of Movement disorders, Department of Neurology. Bridged basic science and clinical divisions. Was promoted 2 times in 5 years based on productivity

Movement Disorders Clinical Fellowship. Evaluated and treated patients with various neurological disorders including Parkinson's disease, Neurodegenerative Dementias, Essential Tremor, Tics, Dystonia, Huntington's disease and participated in research projects in clinical genetics